surgical robots

The US Food and Drug Administration has issued draft guidance for surgical robots, outlining its thinking for developers and manufacturers of robotic surgical systems. The document is expected to shape regulatory expectations in a growing medtech field, and industry stakeholders will likely be able to comment before a final version is adopted.

Researchers report that fundamental kinematic indicators—the basic motion patterns of a surgeon's hands during robot-assisted procedures—can predict both levels of surgical expertise and clinical outcomes for patients. The findings, published in Nature, suggest objective movement data could be used to assess and train surgeons, moving evaluation beyond subjective supervision and toward measurable performance benchmarks in robotic surgery.

The US Food and Drug Administration has released draft guidance covering cardiovascular surgical robots, outlining its current thinking for developers and manufacturers of these devices. The document, reported by Cardiovascular Business, is expected to shape how robotic systems for heart procedures are designed, tested and cleared. Stakeholders in medical robotics will likely review the draft and submit comments before final guidance is issued.

A report covered by the Asahi Shimbun says women are selected less often than men to perform robot-assisted surgeries, pointing to a gender gap in access to this advanced surgical technology and training. The finding has drawn attention to inequality within surgical specialties as robotic systems become more common in operating rooms worldwide.

Medtronic, the global medical device maker, is investing in robotics and artificial intelligence for healthcare, raising questions among investors about the strategy behind the expansion. The move points to the company's push to grow beyond traditional devices into surgical robotics and AI-driven care, sectors where competitors are also racing to establish a lead.

Analysis in the medical device industry examines how regulators must adapt as AI moves beyond software and into surgical robots that physically operate on patients. The piece argues that existing approval frameworks, built for diagnostic tools and imaging, may not be suited to autonomous or semi-autonomous systems whose behaviour can change after deployment, raising questions about oversight, accountability and post-market monitoring.